- This event has passed.
The Steps Beyond The Science- Paediatric Medicines For Infectious Diseases
February 6 @ 12:45 pm - 2:15 pm
Organized by GlaxoSmithKline and ViiV Healthcare
The Steps Beyond The Science –
Paediatric Medicines For Infectious Diseases
Thursday, February 6, 2020
12:45 PM – 2:15 PM
International Museum of the Red Cross and Red Crescent
17 Avenue de la Paix
Join us to discover how partnerships can accelerate progress to treat infectious diseases for paediatric populations in developing nations.
Moderated by Claire Doole whose task will be to ensure the discussion focuses on the real case studies and evidence of progress made to date in advancing infectious disease treatments for paediatric populations and explore how lessons learnt can be applied across diseases. We will identify challenges and opportunities along the solution pathway – from product development to the downstream steps that require coordination and partnerships to secure treatment scale-up, delivery, national adoption, community engagement and capacity building.
A light lunch will be served.
Please note that places are limited and will be allocated on a first come, first served basis.
The event is part of the “Steps Beyond the Science” series. This series aims to gather multilateral organisations, governments, academia, civil society and industry to discuss pressing global health challenges and calls on all partners to take forward the insights they hear into their everyday work in global health, in order to catalyse action and make a difference to lives around the world. Previous discussions in the series have been held at WHA 2019 and UNGA 2019.
Each year millions of children and adolescents die from preventable infectious diseases and mostly in the developing world. HIV/AIDS is the biggest killer of adolescents in Sub-Saharan Africa and the second biggest killer of adolescents globally. TB has overtaken HIV as the world’s greatest infectious killer. And 405,000 people died of malaria in 2018, with 67% of these deaths in children under five.
New and effective medicines remain vital to addressing these unmet global health needs. And it is critical to ensure sustainable, timely and effective pathways to patients so that their impact is realised.
Developing and delivering treatments for paediatric populations presents unique challenges. Partnerships are essential in order to overcome these challenges and create opportunities for accelerating the impact of developments.